Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04761627 · ClinicalTrials.gov registry record · Phase 3
A Study to Investigate Interchangeability of ABP 654 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
A Phase 3 study of Psoriasis, sponsored by Amgen.
- Completed
- Registry status
- Phase 3
- Development phase
- 494
- Enrollment target
- 20
- Study locations
NCT04761627 is a Phase 3 study of Psoriasis that has completed, run by Amgen. The registered enrollment target is 494 participants, roughly in line with the 485-participant average among 125 other Psoriasis trials with a reported enrollment target. The trial reports 20 study locations across 11 states.
The verdict
NCT04761627, a Phase 3 study of Psoriasis, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 494 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of the study is to evaluate pharmacokinetic similarity, efficacy, safety and immunogenicity of multiple switches between ustekinumab and ABP 654 compared with continued use of ustekinumab in participants with moderate to severe plaque psoriasis.
Conditions Studied
Interventions
- DRUG Ustekinumab
- DRUG ABP 654
Study Locations (20)
Florida
- Encore Research Group-Jacksonville Center for Clinical Resea - Jacksonville
- Altus Research, Inc. - Lake Worth
- International Dermatology Research, Inc. - Miami
- Leavitt Medical Associates of Florida d/b/a Ameriderm Research - Ormond Beach
- Riverchase Dermatology and Cosmetic Surgery - Pembroke Pines
- Olympian Clinical Research - Tampa
California
- Zenith Research Inc. - Beverly Hills
- Center for Dermatology Clinical Research, Inc. - Fremont
- Quest Dermatology Research - Northridge
- Southern California Dermatology, Inc - Santa Ana
Georgia
- Hamilton Research, LLC - Alpharetta
- Advanced Medical Research PC - Sandy Springs
Arkansas
- Burke Pharmaceutical Research - Hot Springs
Illinois
- Dundee Dermatology - West Dundee
Indiana
- DS Research - Clarksville
Iowa
- Integrated Clinical Trial Services Inc. - West Des Moines
Kansas
- Kansas Medical Clinic, PA - Topeka
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 494 participants |
| Start Date | 2021-03-24 |
| Est. Completion | 2023-02-28 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04761627
The ClinicalTrials.gov registry entry for NCT04761627 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 494 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 485-participant average among 125 other Psoriasis trials with a reported enrollment target. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Psoriasis appearing as the primary indexed condition, and to 2 interventions - of which Ustekinumab is the first listed.
NCT04761627 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Florida, California, Georgia.
Frequently Asked Questions
What is clinical trial NCT04761627 about?
NCT04761627 is a clinical study titled "A Study to Investigate Interchangeability of ABP 654 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis". The purpose of the study is to evaluate pharmacokinetic similarity, efficacy, safety and immunogenicity of multiple switches between ustekinumab and ABP 654 compared with continued use of ustekinumab in participants with moderate to severe plaque psoriasis.
What is the current status of trial NCT04761627?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 494 participants. The study started on 2021-03-24. Estimated completion is 2023-02-28.
What conditions does trial NCT04761627 study?
This clinical trial studies the following conditions: Psoriasis.
What interventions are being tested in trial NCT04761627?
The interventions under investigation include: Ustekinumab (DRUG), ABP 654 (DRUG).
Who is sponsoring clinical trial NCT04761627?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04761627 being conducted?
This trial has 20 study locations across Arkansas, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977
ACTIVE NOT RECRUITING · Phase 3
-
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
ACTIVE NOT RECRUITING · Phase 3
-
Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis
ACTIVE NOT RECRUITING · Phase 3
-
Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Participants
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.